Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma
- 1 August 2001
- Vol. 92 (3), 595-600
- https://doi.org/10.1002/1097-0142(20010801)92:3<595::aid-cncr1359>3.0.co;2-d
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Phase I and Pharmacologic Study of Sequences of Gemcitabine and the Multitargeted Antifolate Agent in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2000
- Clinical and Pharmacokinetic Phase I Study of Multitargeted Antifolate (LY231514) in Combination With CisplatinJournal of Clinical Oncology, 1999
- A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalationCancer Chemotherapy and Pharmacology, 1999
- Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II StudyJournal of Clinical Oncology, 1999
- Review on evidence-based cancer medicineAnnals of Oncology, 1998
- Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overviewAnti-Cancer Drugs, 1995
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995